Prostate Cancer Daily

Zachary Klaassen discusses hydrogel spacer placement and resident education, drawing on approximately 250 Barrigel® procedures performed since FDA clearance in 2022.

Neeraj Agarwal speaks with Nobuaki Matsubara about phase one results for mevrometostat, an EZH2 inhibitor added to a continued ARPI backbone in patients with castration-resistant prostate cancer who had progressed on enzalutamide plus abiraterone or abiraterone alone.